FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W162220021> ?p ?o ?g. }

• W162220021 endingPage "8" @default.
• W162220021 startingPage "487" @default.
• W162220021 abstract "One of the challenges facing clinical psychiatry is how to treat bipolar depression effectively.1 Surprisingly, its neurobiology and rational decisions about its treatment remain somewhat of a mystery. Recent findings have even called into question the role of traditional antidepressants in bipolar depression when other classes of drugs may be more effective first-line treatments for this illness.2 Setting aside the thorny question of whether antidepressants induce manic switches or rapid cycling, it seems worthwhile to consider recent clinical studies and try to make sense of their implications for the neurobiology of bipolar depression.Treating bipolar depression with antidepressants remains a popular option in clinical practice and published guidelines. Most clinicians choose the drug or class of drugs, usually selective serotonin reuptake inhibitors and bupropion, that is most effective and best tolerated.1 However, the recently published results from the STEP-BD project found no benefit to adding an antidepressant (paroxetine or bupropion; n = 179) compared with placebo (n = 187) to a mood stabilizer in a large naturalistic sample of patients with bipolar I and II disorders.2 This intriguing finding certainly questions whether antidepressants, a common intervention for bipolar depression, are effective in the treatment of this remarkably disabling and difficult-to-manage condition.Practice guidelines and clinical consensus support the use of mood stabilizers such as lithium or anticonvulsants either as monotherapy or add-on therapy for bipolar depression.1 In general, this treatment is not considered to be highly effective for bipolar depression because symptoms often improve slowly or incompletely. When lithium is included as a comparator in maintenance trials for new potential mood stabilizers, results show it is effective in the prevention of manic relapses, but limited in the prevention of relapses into depression.3I have had a long interest in bipolar depression. In a proof of principle study, my research colleagues and I questioned whether adding a second mood stabilizer could treat depressive symptoms as effectively as adding an antidepressant, and we were surprised to see that both treatments had such a similar effect.4 A recent meta-analysis of the treatment of bipolar disorder showed that valproate had a surprising ability to prevent depressive relapses, and at least a few studies have suggested the drug may be an effective treatment for acute depressive symptoms in bipolar disorder.1,5 In light of the recent data suggesting that antidepressants may have little effect when added to a mood stabilizer, this treatment option might warrant reconsideration and further study. To make the situation even less clear, at least one anticonvulsant, lamotrigine, lacks antimanic properties, and although it is an adequate antidepressant agent in bipolar depression, it is not as effective in the treatment of major depressive disorder.6 Carbamazepine has fallen out of favour with many clinicians owing to adverse effects and complicated drug interactions; however, in my experience, it can be a very useful agent for the treatment of bipolar depression.1 Taken together, traditional mood stabilizers, including anticonvulsants, are potentially effective treatments for bipolar depression.The increasing acceptance of atypical antipsychotics as mood stabilizers was first based on their proven ability to treat acute mania and, more recently, on their effectiveness in the treatment of bipolar disorder and their acute antidepressant effects. Olanzapine has been shown to have acute antidepressant effects in bipolar disorder either alone or in combination with fluoxetine.7 Although quetiapine has been established for some time as an agent with antidepressant effects in bipolar disorder, some recent data have shown even more impressive effects. Two studies involving close to 1500 depressed patients with bipolar I and II disorders compared quetiapine with placebo and either lithium or paroxetine.8,9 In both studies, quetiapine was reported to be more effective in reducing depressive symptoms compared with placebo or the other agent after an 8-week trial. Interestingly, neither lithium nor paroxetine was more effective than placebo. Although few would have argued with the results for lithium before the publication of the STEP-BD results,2 the lack of apparent effect of paroxetine found in that study was an unexpected outcome. Nonetheless, atypical antidepressants are emerging as effective treatments for bipolar depression.Historically, we have extrapolated from the mechanism of action of psychotropic drugs to construct or validate neurobiologic models of psychiatric disorders. Do these results suggest that monoaminergic mechanisms are less important in our understanding of bipolar depression than of unipolar depression? Do the surprisingly encouraging results for anticonvulsants suggest that we should look more closely at either GABAergic (quite popular at one time) or glutamatergic hypotheses for bipolar depression? Since lamotrigine has not been shown to be effective in unipolar depression, this may indeed support such a change in our thinking. Finally, although the effects of atypical antipsychotics offer new options for a phase of bipolar disorder that is difficult to treat, they limit our understanding of the neurobiology of the disorder even further. Theories on the antidepressant effects of antipsychotic medications have ranged from modulating dopamine and serotonin to sharing metabolite properties with other antidepressants to demonstrating intracellular mechanisms for antidepressants and lithium. In sum, it is hard to find a parsimonious and elegant explanation for the emerging effectiveness of these drugs in bipolar depression.It is encouraging to see so many new findings in a previously moribund area of psychiatric research. Although these encouraging clinical data may raise more questions than they answer, they may point to the need to discard older models of the neurobiology of psychiatric disorders, to be open to new data and to explore new treatments." @default.
• W162220021 created "2016-06-24" @default.
• W162220021 creator A5060619422 @default.
• W162220021 date "2008-11-01" @default.
• W162220021 modified "2023-09-23" @default.
• W162220021 title "What is the best treatment for bipolar depression?" @default.
• W162220021 cites W1521911962 @default.
• W162220021 cites W1977252830 @default.
• W162220021 cites W2099017168 @default.
• W162220021 cites W2102975616 @default.
• W162220021 cites W2111355579 @default.
• W162220021 cites W2126891996 @default.
• W162220021 cites W2166423384 @default.
• W162220021 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2575757" @default.
• W162220021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18982170" @default.
• W162220021 hasPublicationYear "2008" @default.
• W162220021 type Work @default.
• W162220021 sameAs 162220021 @default.
• W162220021 citedByCount "3" @default.
• W162220021 countsByYear W1622200212013 @default.
• W162220021 countsByYear W1622200212014 @default.
• W162220021 countsByYear W1622200212016 @default.
• W162220021 crossrefType "journal-article" @default.
• W162220021 hasAuthorship W162220021A5060619422 @default.
• W162220021 hasConcept C118552586 @default.
• W162220021 hasConcept C139719470 @default.
• W162220021 hasConcept C142724271 @default.
• W162220021 hasConcept C15744967 @default.
• W162220021 hasConcept C162324750 @default.
• W162220021 hasConcept C2776174506 @default.
• W162220021 hasConcept C2776809841 @default.
• W162220021 hasConcept C2776867660 @default.
• W162220021 hasConcept C2777843972 @default.
• W162220021 hasConcept C2778541603 @default.
• W162220021 hasConcept C2779177272 @default.
• W162220021 hasConcept C2779908668 @default.
• W162220021 hasConcept C2780550438 @default.
• W162220021 hasConcept C2780733359 @default.
• W162220021 hasConcept C2781246090 @default.
• W162220021 hasConcept C542102704 @default.
• W162220021 hasConcept C558461103 @default.
• W162220021 hasConcept C71924100 @default.
• W162220021 hasConceptScore W162220021C118552586 @default.
• W162220021 hasConceptScore W162220021C139719470 @default.
• W162220021 hasConceptScore W162220021C142724271 @default.
• W162220021 hasConceptScore W162220021C15744967 @default.
• W162220021 hasConceptScore W162220021C162324750 @default.
• W162220021 hasConceptScore W162220021C2776174506 @default.
• W162220021 hasConceptScore W162220021C2776809841 @default.
• W162220021 hasConceptScore W162220021C2776867660 @default.
• W162220021 hasConceptScore W162220021C2777843972 @default.
• W162220021 hasConceptScore W162220021C2778541603 @default.
• W162220021 hasConceptScore W162220021C2779177272 @default.
• W162220021 hasConceptScore W162220021C2779908668 @default.
• W162220021 hasConceptScore W162220021C2780550438 @default.
• W162220021 hasConceptScore W162220021C2780733359 @default.
• W162220021 hasConceptScore W162220021C2781246090 @default.
• W162220021 hasConceptScore W162220021C542102704 @default.
• W162220021 hasConceptScore W162220021C558461103 @default.
• W162220021 hasConceptScore W162220021C71924100 @default.
• W162220021 hasIssue "6" @default.
• W162220021 hasLocation W1622200211 @default.
• W162220021 hasOpenAccess W162220021 @default.
• W162220021 hasPrimaryLocation W1622200211 @default.
• W162220021 hasRelatedWork W136829902 @default.
• W162220021 hasRelatedWork W1966206753 @default.
• W162220021 hasRelatedWork W197797046 @default.
• W162220021 hasRelatedWork W1997006810 @default.
• W162220021 hasRelatedWork W2007761862 @default.
• W162220021 hasRelatedWork W2046117113 @default.
• W162220021 hasRelatedWork W2077648424 @default.
• W162220021 hasRelatedWork W2110829161 @default.
• W162220021 hasRelatedWork W2124907633 @default.
• W162220021 hasRelatedWork W2142305013 @default.
• W162220021 hasRelatedWork W2179045181 @default.
• W162220021 hasRelatedWork W2324838455 @default.
• W162220021 hasRelatedWork W2412403201 @default.
• W162220021 hasRelatedWork W2419596459 @default.
• W162220021 hasRelatedWork W2469938013 @default.
• W162220021 hasRelatedWork W2731782183 @default.
• W162220021 hasRelatedWork W3033157912 @default.
• W162220021 hasRelatedWork W3183853397 @default.
• W162220021 hasRelatedWork W35865482 @default.
• W162220021 hasRelatedWork W2336961223 @default.
• W162220021 hasVolume "33" @default.
• W162220021 isParatext "false" @default.
• W162220021 isRetracted "false" @default.
• W162220021 magId "162220021" @default.
• W162220021 workType "article" @default.